Welcome to our dedicated page for Tenet Healthcare SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenet Healthcare Corporation filings document the regulatory record of a healthcare services company with hospital operations, an ambulatory surgery platform and Conifer revenue cycle management services. Its 8-K reports disclose operating results, financial outlook updates, Regulation FD information, material agreements involving Conifer, and debt financing matters tied to senior secured first lien notes and senior notes.
Tenet's proxy and current reports also cover board composition, shareholder voting matters, executive compensation, officer transition agreements, controller and principal accounting officer appointments, equity-award terms, common stock, senior-note securities and related governance disclosures. These filings connect THC's capital structure and management oversight to its Ambulatory, Hospital and Conifer business activities.
Tenet Healthcare Corporation furnished a Form 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The company attached the release as Exhibit 99.1 and incorporated it by reference.
The information was furnished, not filed, under the Exchange Act. Tenet lists its securities as common stock (THC) and 6.875% Senior Notes due 2031 (THC31).
Saumya Sutaria, identified as both a director and the CEO of Tenet Healthcare Corp (THC), reported the sale of common stock on 09/10/2025. The Form 4 discloses two separate sale transactions: 59,456 shares sold at a weighted average price of $190.48 (prices ranged $190.14–$191.05) and 19,306 shares sold at a weighted average price of $191.70 (prices ranged $191.18–$192.06), for a total of 78,762 shares sold. Following the reported transactions, beneficial ownership is reported as 387,989 shares after the first set of sales and 368,683 shares after the second set. The Form 4 is dated and signed on behalf of Ms. Sutaria by an attorney-in-fact, Chad J. Wiener, on 09/12/2025. The filing includes undertakings to provide breakouts of shares sold at each price upon request.
Form 144 notice for proposed sale of securities. The filing reports an intended sale of 78,762 shares of Common stock through Fidelity Brokerage Services LLC on or about 09/10/2025 with an aggregate market value of $15,025,892.48. The shares were acquired on 08/31/2025 via restricted stock vesting from the issuer and the payment type is listed as compensation. The filing states there were no securities sold in the past three months. Several issuer identification fields (including the issuer name and SEC file number) are not populated in the provided content.
Saumya Sutaria, CEO and director of Tenet Healthcare Corporation (THC), reported vesting and related transactions on 08/29/2025. A grant of 53,341 time-based restricted stock units from 2021 vested in full and converted one-for-one into 53,341 shares. Following the vesting and subsequent share transfers to cover taxes and other dispositions, the filing shows Sutaria beneficially owned 447,445 shares.
The filing records shares withheld for taxes: 27,087 shares withheld upon vesting and 54,174 shares delivered to satisfy withholding for performance share units. The report states a reported disposition of 53,341 shares under transaction code M for the conversion event and lists a closing stock price of $184.33 used in the withholding calculation.
Insider sale disclosed: Tenet Healthcare director Christopher S. Lynch reported a sale of 12,350 shares of Tenet Healthcare Corp (ticker: THC) on 08/28/2025 at a reported price of $183.44 per share. The Form 4 was signed by Chad J. Wiener as attorney-in-fact on 08/29/2025. The sale is reported as a direct disposition by the reporting person.
Lisa Y. Foo, Executive Vice President and Chief Operating Officer of Tenet Healthcare Corporation (THC), reported the sale of 8,000 shares of Tenet common stock on 08/20/2025 at a weighted average price of $179.53 per share. After the reported disposition, the reporting person beneficially owned 20,878 shares, held directly. The Form 4 was signed by an attorney-in-fact, Chad J. Wiener, on 08/22/2025. The filer indicates the aggregate sale included multiple transactions with prices ranging from $179.22 to $179.74, and offers to provide detailed per-transaction quantities on request.
Tenet Healthcare insider sale: Director Christopher S. Lynch sold 3,952 shares of Tenet Healthcare Corporation common stock on 08/19/2025 at a reported price of $176.39 per share, leaving him with 12,358 shares beneficially owned after the sale. The Form 4 was signed by an attorney-in-fact on 08/21/2025. The filing identifies Lynch as a director and the transaction is a direct sale of common stock.
Tenet Healthcare (THC) Form 144 summary: An insider filed a notice to sell 8,000 common shares through Fidelity Brokerage Services on or about 08/20/2025. The filing lists an aggregate market value of $1,436,278.72 and total shares outstanding of 88,351,000, meaning the proposed sale equals approximately 0.0091% of outstanding shares. All 8,000 shares were acquired by restricted stock vesting from the issuer as compensation on dates in 2023 and 2024 (658; 1,088; 3,946; 2,308). The filer reports no securities sold in the past three months and makes the required representation about lack of undisclosed material information.
Tenet Healthcare exec Sun Park had 20,707 restricted stock units (RSUs) convert into common stock on 08/13/2025 after a relocation-based vesting condition was met. The RSUs convert one-for-one into common shares, bringing Park's post-transaction direct beneficial ownership to 23,392 shares. To cover taxes on vesting, 8,813 shares were withheld at an effective value of $171.87 per share, leaving 14,579 shares retained. The RSUs were originally granted on July 17, 2023 under the 2019 Stock Incentive Plan and exercised via standard vesting mechanics.
Saumya Sutaria, CEO and director of Tenet Healthcare Corporation (THC), received a grant of 106,682 shares of common stock that vested as performance-based restricted stock on 08/13/2025. The filing states the award was earned after the Human Resources Committee certified achievement of performance targets for the period January 1, 2021 to June 30, 2025. Following the transaction, Sutaria beneficially owns 475,365 shares. The Form 4 was signed by an attorney-in-fact on 08/15/2025.